N A Shamalov

Plain English
This study examined the use of a new treatment called non-immunogenic staphylokinase for patients experiencing acute ischemic stroke, specifically looking at its safety and effectiveness. Of the 17,636 patients treated, only 2% experienced serious bleeding within 36 hours, and 9% died within 90 days, while 61% showed good recovery. These results indicate that staphylokinase is a safe and effective option for treating strokes when given within 4.5 hours of symptom onset. Who this helps: This benefits stroke patients who need timely treatment.

Plain English
This study looked at the effectiveness of two treatments for stroke caused by a blockage in the middle cerebral artery: endovascular thrombectomy (EVT) alone versus EVT combined with intravenous thrombolysis (IVT). Researchers analyzed data from 801 patients and found that those who received IVT were more likely to have successful first-pass treatment (49% vs. 40%) and experienced lower in-hospital mortality rates (23% vs. 34%). This matters because it shows that adding IVT to EVT can lead to better outcomes for stroke patients while maintaining a similar risk for complications. Who this helps: This benefits stroke patients and healthcare providers involved in their treatment.

Plain English
This study looked at the use of a new drug called tenecteplase for treating ischemic stroke in three patients in Russia. All three patients showed major improvements in their neurological symptoms within an hour of receiving the drug, and there were no increases in stroke damage after 24 hours. This matters because it highlights that tenecteplase is a safe and effective option for stroke treatment, leading to better patient outcomes. Who this helps: This helps stroke patients and doctors treating them.

Plain English
This study looked at the use of the drug Fortelyzin to treat patients who had an acute ischemic stroke (AIS) when they received treatment between 4.5 and 24 hours after their symptoms started. Researchers found that 61% of patients treated within the first 4.5 hours had a good recovery, while 65% of those treated later also had a good recovery, showing that treatment is still effective even when started later. The rates of serious complications were similar in both groups, indicating that Fortelyzin is a safe option for stroke patients, regardless of when they receive treatment. Who this helps: This helps stroke patients who may not get to the hospital within the first few hours of their symptoms.

Plain English
This study looked at how safe and effective a drug called Fortelyzin is for people having an acute ischemic stroke, specifically when used during treatments that involve both thrombolysis and thrombectomy. Out of 1,116 patients, 38% had a good recovery after 90 days, while 29% died in that time. The findings are important because they show that Fortelyzin can be a useful option in treating stroke patients in everyday healthcare settings. Who this helps: This benefits doctors and patients dealing with acute ischemic strokes.

Plain English
This study looked at how well different methods can predict recovery after a specific treatment for stroke called thromboextraction. Researchers analyzed data from 90 patients and found that 69 had good recoveries, while 21 did not. The best predictors of recovery were the volume of brain tissue with low blood flow (less than 30%) and scores from brain scans assessed by expert doctors, which can help identify which patients are likely to do well after treatment. Who this helps: This benefits patients who have suffered a stroke and their doctors, as it aids in better treatment planning.

Plain English
This paper outlines clinical guidelines for understanding and managing cognitive disorders in older adults. It emphasizes the importance of recognizing different types of cognitive issues, their causes, and appropriate treatment options. Following these guidelines can lead to better care for elderly patients, improving their quality of life. Who this helps: Older adults with cognitive disorders and their healthcare providers.

Plain English
This research studied how well the THRIVE scale predicts the outcomes of older patients (60 years and up) with acute ischemic stroke (AIS) who were treated with a new drug called staphylokinase, compared to a standard treatment called alteplase. The analysis showed that the THRIVE scale is a reliable tool for predicting health outcomes; for instance, its accuracy in predicting 90-day all-cause mortality was 80% for staphylokinase and 76% for alteplase. This is important because it can help doctors better gauge how patients might recover after treatment, ensuring that older patients receive the best possible care. Who this helps: Patients aged 60 and older who have had a stroke.

Plain English
This study looked at how new treatments for ischemic stroke (IS) are being used in Russia from 2015 to early 2025. Researchers found that more patients are getting treated quickly after symptoms start, with those admitted within 4.5 hours rising from 23% in 2015 to 31% in 2024. The use of reperfusion treatments, like IVT and thrombectomy, also increased significantly, leading to a reduction in mortality rates from 16.8% in 2015 to 12.6% in 2025. This matters because faster and better treatment can help more people survive strokes and recover their abilities. Who this helps: This helps patients who suffer from strokes and improve outcomes through timely medical interventions.

Plain English
This study examined the effectiveness of a medication called Mexidol for patients recovering from ischemic stroke, comparing it to a placebo. In the trial involving 304 patients, those who received Mexidol showed significant improvements in disability and neurological symptoms, with more patients reporting better mobility and less cognitive impairment than those who received the placebo. Specifically, the Mexidol group had a median improvement on the disability scale compared to the start of treatment, indicating that it helps patients recover better after a stroke. Who this helps: This research benefits patients recovering from ischemic stroke.

Plain English
This study looked at how using teleconsulting in primary vascular units (tele-PVUs) improved access to specialized stroke treatment in Russia. It found that 9.8% of stroke patients treated in these units received thrombolytic therapy, which is higher than the national average, and the time from when symptoms started to when treatment began was also reduced. This is important because it means more patients in rural areas can get life-saving treatment faster. Who this helps: Patients in rural areas who suffer from ischemic strokes.

Plain English
This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options. Who this helps: Patients with acute ischemic stroke and their healthcare providers.

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

Plain English
This study looked at four patients who had ischemic strokes while also being infected with COVID-19. All patients underwent a procedure called mechanical thrombus extraction, which successfully removed a blood clot and led to noticeable improvements in their symptoms. While the immediate results were positive, it's unclear how COVID-19 will affect their recovery in the long run. Who this helps: This helps patients who have had an ischemic stroke, especially those with COVID-19.

Plain English
This study looked at the economic and social impact of stroke in Russia, finding that in 2019, there were over 435,000 stroke cases, with 30% of those patients dying within a year. The total cost of stroke to the Russian economy was more than 490 billion rubles, which is about 0.3% of the country's GDP, and many family members had to change jobs or stop working to care for loved ones. This highlights the heavy burden of stroke not just in terms of healthcare costs, but also in lost productivity and overall economic impact. Who this helps: This information benefits policymakers, healthcare providers, and families affected by stroke.

Plain English
This study looked at how controlling cholesterol levels can help prevent ischemic strokes, which are a major cause of death and disability. Researchers found that managing dyslipidemia, or unhealthy cholesterol levels, is crucial in reducing the risk of both first-time and repeated strokes. Effective management of cholesterol can significantly decrease the chances of experiencing these life-threatening events. Who this helps: This benefits patients at risk of strokes and healthcare providers aiming to improve patient outcomes.

Plain English
This study focused on a unique case where a patient with an ischemic stroke was treated using a novel drug called non-immunogenic staphylokinase after neutralizing the blood-thinning effects of dabigatran etexilate. The researchers found that this approach could effectively lead to the dissolution of blood clots without the complications typically faced with standard treatments, thus providing a potential new option for stroke therapy. This matters because it expands the treatment possibilities for patients using certain blood thinners, which previously made it risky to use clot-dissolving drugs. Who this helps: This helps patients with ischemic stroke who are on blood thinners.

Plain English
This study focused on patients with issues related to the marginal mandibular branch of the facial nerve, which affects the muscles involved in lowering the lip and chin. Researchers looked at six patients, averaging 40 years old, who struggled with this condition for about 35 days without improvement. They found that those with a change in muscle performance of less than 90% had a good chance of recovery with specific exercises, while those with more severe changes required surgery for improvement. Who this helps: This research benefits patients dealing with facial nerve issues and their doctors by providing clearer treatment options.

Plain English
This study compared two treatments for patients suffering from acute ischemic stroke: non-immunogenic staphylokinase (NS) and alteplase (A). Out of 336 patients, 50% of those who received NS had a good recovery after 90 days, while 41% of those who received alteplase did, showing that NS may be a more effective option. It also resulted in fewer serious complications, with 13% of NS patients experiencing significant side effects compared to 22% in the alteplase group. Who this helps: This helps patients who are dealing with acute ischemic strokes.

Plain English
This study looked at the use of a drug called Revelisa to treat people who had ischemic strokes, which happen when blood flow to the brain is blocked. Researchers treated 550 patients and found that about 45% showed significant improvement in their condition one day after treatment. Additionally, 68.5% of patients had good recovery by the time they were discharged from the hospital after 90 days. Who this helps: This research benefits patients experiencing ischemic strokes and their healthcare providers by showing that Revelisa can effectively reduce symptoms and improve recovery.

Plain English
This study examined how COVID-19 affects the nervous system, finding that severe cases of the virus often lead to serious neurological issues, such as stroke and muscle disorders. In patients with severe COVID-19, about 20-30% experienced neurological problems, which were more common in those with existing health issues like high blood pressure and diabetes. Understanding these connections is crucial for improving treatment and care for affected individuals. Who this helps: This helps patients with COVID-19, especially those with pre-existing health conditions.

Plain English
This study compared a new treatment called non-immunogenic staphylokinase to the standard treatment, alteplase, for patients experiencing an acute ischemic stroke within 4.5 hours of symptoms starting. The results showed that 50% of patients receiving staphylokinase had a favorable recovery 90 days later, compared to 40% of those treated with alteplase. Importantly, staphylokinase was found to be equally effective while also causing fewer serious side effects. Who this helps: Patients with acute ischemic stroke and their healthcare providers benefit from these findings.

Plain English
Researchers explored how COVID-19 affects the brain, finding that many patients experience lasting neurological symptoms that can persist for many months, leading to a new term called "Post-COVID-19 Condition." The Advisory Board of neurologists recommended a unified treatment approach for managing these complications, emphasizing the need for a special program to monitor patients post-COVID-19, which includes assessing cognitive functions to catch any neurodegenerative issues early. This is vital as it ensures patients receive appropriate care to address these long-term effects of the virus. Who this helps: Patients recovering from COVID-19 with neurological symptoms.

Plain English
This study looked at the use of a drug called Revelisa for treating ischemic stroke patients in real-life hospital settings. Out of 223 patients treated, 7.1% experienced complications from bleeding in the brain, and 13.9% died during their hospital stay. After treatment, nearly half of the patients (48.2%) showed good recovery at discharge, which is comparable to results from other treatments like alteplase. Who this helps: Patients who suffer from ischemic strokes.

Plain English
This study looked at how well antiepileptic medications work for patients who have specific types of epilepsy with myoclonic seizures. Out of 103 patients, 67% found complete relief from seizures, and 23% saw their seizures reduced by half or more, while 10% did not benefit from the treatment. The success rates varied depending on the type of epilepsy, with juvenile myoclonic epilepsy showing the best results. Who this helps: This benefits patients with epilepsy, particularly those diagnosed with juvenile myoclonic epilepsy.

Plain English
This study looks at how COVID-19 affects the nervous system, finding that serious coronavirus infections can lead to severe neurological issues like strokes and Guillain-Barré syndrome, particularly in patients with underlying health problems like heart disease and diabetes. The authors highlight that the worse the COVID-19 symptoms, the more likely a patient is to experience neurological complications, which is critical for managing care. The research also discusses how COVID-19 can worsen existing nerve-related diseases like multiple sclerosis and suggests a plan for treating stroke and MS patients during the pandemic to reduce infection risk. Who this helps: This information helps doctors and healthcare providers in treating patients with COVID-19 and neurological conditions.

Plain English
This study focused on improving cholesterol-lowering treatments for patients who have suffered an ischemic stroke. Researchers created a clear plan for doctors to follow, which includes using medications like statins, ezetimibe, and PCSK9 inhibitors in specific steps to lower bad cholesterol levels in these patients. Lowering cholesterol is crucial because high levels are a major risk factor for further strokes and heart problems. Who this helps: This helps patients who have had an ischemic stroke and their doctors.

Plain English
The study looked at how well people in Moscow know the signs of a stroke and how they respond in emergencies. It found that 65% of people feel confident they can recognize stroke symptoms, but many mix up strokes with other medical conditions. While 94% said they would call an ambulance, some still hold misconceptions about what to do. This is important because better knowledge can lead to faster and more effective treatment for stroke patients. Who this helps: This helps patients who might suffer from a stroke and need immediate help.

Plain English
This study looked at the genetic factors that can increase the risk of stroke, both types: bleeding (hemorrhagic) and blockage (ischemic). Researchers found that certain genes are linked to inflammation, blood clotting, and cholesterol production, which are important in stroke development. Understanding these genetic traits can help identify people at very high risk for stroke, allowing for early preventive actions to reduce the chances of having a stroke. Who this helps: This benefits patients at risk of stroke and their healthcare providers.

Plain English
This research examined the types of strokes among people aged 25 and older in seven regions of Russia from 2009 to 2016. It found that the number of unspecified strokes dropped significantly, from 4.7% to 0.4%, and the mortality rate for ischemic strokes decreased over time. Specifically, the occurrence of cardioembolic strokes reduced from 35% to 21%, indicating better diagnostic methods and improved patient care for stroke prevention and treatment. Who this helps: Patients who are at risk of strokes and healthcare providers involved in their treatment.

Plain English
This research study focused on improving medical care for stroke patients in Russia over the past ten years. The implementation of new treatment methods and better training for medical staff led to a significant decrease in disability and death rates from strokes. This matters because it shows that investing in healthcare can save lives and improve the quality of life for those affected by strokes. Who this helps: Patients who have suffered a stroke and their families.

Plain English
This study looked at how effective a treatment called intermittent pneumatic compression (IPC) is for preventing blood clots in the legs and lung problems in neurological patients in intensive care. It involved 101 patients, with 52 receiving IPC and 49 getting standard treatment. The findings showed that IPC significantly lowers the risk of blood clots and related deaths in the first 20 days for patients with strokes and mobility issues. Who this helps: This helps patients in intensive care recovering from strokes.

Plain English
This study looked at how effective and safe a drug called mexidol is for patients recovering from a type of stroke known as hemispheric ischemic stroke. Involving 151 patients, results showed that those receiving mexidol had better recovery scores than those getting a placebo: specifically, their scores on a disability scale improved significantly, and more patients showed no movement problems at the end of treatment. This matters because it shows that mexidol can help stroke patients recover more effectively, especially those with diabetes. Who this helps: This benefits stroke patients and their doctors by providing a new treatment option to improve recovery.

Plain English
This study looked at how effective a treatment called cortexin is for patients who have had an acute ischemic stroke, which occurs when blood flow to the brain is blocked. Out of 272 patients in the study, those who received two courses of cortexin showed the best results, with improved recovery compared to those who did not receive the treatment. The findings also indicated that using cortexin is cost-effective, making it a recommended option for helping patients recover from stroke. Who this helps: This helps patients recovering from acute ischemic stroke.

Plain English
The study examined how specific genetic variations (polymorphisms) in certain genes are linked to the risk of developing a stroke in Russian and Ukrainian people. In Russians, those with the DD genetic type have a 40% higher risk of ischemic stroke, while other genetic types (I/I and I/D) are linked to a lower risk by 30%. In contrast, Ukrainian individuals did not show significant genetic associations with stroke risk. Who this helps: This research benefits doctors and researchers by providing insights into genetic risk factors for stroke in different populations.

Plain English
Researchers studied the relationship between certain genes related to blood pressure regulation and blood clotting in people who had ischemic strokes compared to healthy individuals in Central Russia. They found that a specific combination of gene variations (FGB G/-, ACE I/-, MTHFR C/-, and SERPINE1 5G/5G) was linked to a 2.4 times higher risk of having a stroke. This matters because identifying these gene combinations can help target prevention strategies for those at higher risk. Who this helps: This helps patients at risk for strokes and doctors managing their care.

Plain English
This study looked at specific genetic markers in patients from Russia who had experienced ischemic strokes and compared them to healthy individuals. Researchers found that a certain genetic combination (PON1A/-x PON2 GG) was much more common in stroke patients, with a risk increase of 3.4 times compared to the healthy group. This matters because identifying genetic factors linked to strokes can help in understanding who may be at greater risk and improve prevention strategies. Who this helps: Patients at risk of ischemic stroke and their healthcare providers.

Plain English
The study looked at the link between a specific DNA marker, called rs1842993, and the risk of a type of stroke caused by blood clots in Slavic individuals. Out of 950 patients, researchers discovered that those with this DNA marker had a higher risk for cardioembolic strokes. This finding is important because it may help identify individuals at risk for these strokes, allowing for earlier intervention and better prevention strategies. Who this helps: This helps patients at risk for cardioembolic strokes and their doctors in managing stroke prevention.

Plain English
This research studied two specific genetic variations (rs10912745 and rs4916375) in people who had an ischemic cardioembolic stroke compared to a control group. The researchers found that these genetic variations were significantly different between the two groups, suggesting that they increase the likelihood of having this type of stroke. This is important because it helps identify individuals at higher risk for stroke, which could lead to better prevention strategies. Who this helps: This helps patients at risk of ischemic strokes and their doctors.

Plain English
This study looked at how well brain blood flow can be measured using a special type of CT scan in patients who have just had an ischemic stroke. Researchers found that within the first 3 hours after the stroke, there were clear differences in blood flow between the damaged part of the brain and the healthy side, and these differences continued for 24 hours. Understanding these blood flow patterns can help doctors make better treatment decisions, even for patients outside the usual treatment time frame of 3 to 4.5 hours after a stroke. Who this helps: This helps patients who have suffered an ischemic stroke.

Plain English
This study looked at how certain markers in the body relate to the risk of complications and death after an ischemic stroke, which occurs when blood flow to the brain is blocked. It involved 62 patients and found that higher levels of a substance called rennin indicated a higher risk of severe bleeding in the brain, while higher levels of fibrinogen on day 4 could predict a negative outcome. These findings are significant because they help doctors identify which patients are at a greater risk of complications, allowing for better management of treatment after a stroke. Who this helps: This helps patients and doctors by providing insights for better stroke care and monitoring.

Plain English
This study looked at how fibrinogen levels in the blood can help predict the risks and effectiveness of a treatment for patients who have had an ischemic stroke. It found that patients with fibrinogen levels below 330 mg/dl had the best recovery rates and the lowest risk of complications, while those with levels above 423 mg/dl faced much higher death rates and poorer recovery. These findings are important because they can guide doctors in assessing stroke patients and deciding on treatment strategies. Who this helps: This helps doctors treating stroke patients.

Plain English
This study looked at two specific genetic variations in the PDE4D gene among 577 stroke patients and 270 healthy individuals in Moscow. Researchers found that certain gene types (AA and AG) were linked to a 1.6 times higher risk of having a stroke compared to those without these variations. This finding is important because it helps identify individuals at greater risk for strokes, which can lead to better prevention and treatment strategies. Who this helps: Patients at risk of stroke and their doctors.

Plain English
This study looked at two gene variations (SNP41 and SNP87) in the PDE4D gene to see if they are linked to the risk of ischemic stroke in people from Moldova. The researchers found no significant connection between these gene variations and having a stroke. This is important because understanding genetic factors can help in assessing stroke risks and improving prevention strategies. Who this helps: This information benefits doctors and researchers studying stroke prevention and genetics.

Plain English
This study looked at specific DNA markers in people from Russia and Moldova to see if they are linked to the risk of having an acute ischemic stroke. The researchers found that these genetic variations did not show any connection to stroke risk in either group. This is important because understanding genetic factors can help identify who is at risk for stroke, but in this case, these markers do not provide useful information. Who this helps: This helps patients and doctors understand that these specific genetic markers are not useful for predicting stroke risk.

Plain English
This study examined the relationship between certain markers in the blood and the occurrence of hemorrhagic transformation (HT) in patients who had ischemic strokes. Researchers found that on the first day after the stroke, patients who experienced HT had significantly higher levels of renin, endothelin 1-21, and neuron-specific enolase compared to those who did not have HT. Understanding these markers is important because they could help predict which patients are at higher risk for developing serious complications after a stroke. Who this helps: This helps doctors in identifying stroke patients who may face increased risks, allowing for better management and treatment.

Plain English
Researchers looked at two variations of the PDE4D gene in people who had a stroke in Moscow, comparing 577 stroke patients to 270 healthy individuals. They found that specific gene patterns (AA and AG) in one variation (SNP41) were linked to a 60% higher risk of having a stroke, while the other gene variation (SNP87) showed no connection to the condition. This is important because it helps identify who might be at greater risk for stroke based on their genetic makeup. Who this helps: Patients at risk for stroke and their healthcare providers.

Plain English
This study looked at how using a special tilt table to help stroke patients after their stroke affects their recovery. It involved 36 patients, with 17 using the tilt table and 19 using a standard bed to change positions. The results showed that those who used the tilt table had better heart rate control and improved daily functioning by day 21 after their stroke. Who this helps: This helps stroke patients by providing a new way to enhance their recovery early on.

Plain English
This study examined how levels of a protein called fibrinogen in the blood relate to the complications of ischemic stroke in patients who did not receive clot-busting treatment. The researchers found that fibrinogen levels between 200 and 350 mg/dL are associated with a lower chance of complications, while levels above 560 mg/dL signal a higher risk of death from the stroke. Understanding these levels helps doctors predict patient outcomes and manage treatment more effectively. Who this helps: This helps patients and doctors by providing crucial information for stroke management.

Plain English
This study looked at 116 patients who had an ischemic stroke, comparing those who received the most effective treatment (rt-PA) to a control group. It found that high levels of fibrinogen (over 450 mg/dl) and white blood cells (over 78%) were linked to worse outcomes, including the risk of bleeding and death after treatment. Understanding these indicators can help doctors predict how well a patient might recover and manage their treatment more effectively. Who this helps: This helps patients who have had a stroke and their doctors in making better treatment decisions.